Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved..
OBJECTIVE: While the course of natural immunization specific to SARS-CoV-2 has been described among convalescent coronavirus disease 2019 (COVID-19) people without HIV (PWOH), a thorough evaluation of long-term serological and functional T- and B-cell immune memory among people with HIV (PWH) has not been reported.
METHODS: Eleven stable PWH developing mild ( n = 5) and severe ( n = 6) COVID-19 and 39 matched PWOH individuals with mild (MILD) ( n = 20) and severe (SEV) ( n = 19) COVID-19 infection were assessed and compared at 3 and 6 months after infection for SARS-CoV-2-specific serology, polyfunctional cytokine (interferon-γ [IFN-γ], interleukin 2 [IL-2], IFN-γ/IL-2, IL-21) producing T-cell frequencies against four main immunogenic antigens and for circulating SARS-CoV-2-specific immunoglobulin G (IgG)-producing memory B-cell (mBc).
RESULTS: In all time points, all SARS-COV-2-specific adaptive immune responses were highly driven by the clinical severity of COVID-19 infection, irrespective of HIV disease. Notably, while a higher proportion of mild PWH showed a higher decay on serological detection between the two time points as compared to PWOH, persistently detectable IgG-producing mBc were still detectable in most patients (4/4 (100%) for SEV PWH, 4/5 (80%) for MILD PWH, 10/13 (76.92%) for SEV PWOH and 15/18 (83.33%) for MILD PWOH). Likewise, SARS-CoV-2-specific IFN-γ-producing T-cell frequencies were detected in both PWH and PWOH, although significantly more pronounced among severe COVID-19 (6/6 (100%) for SEV PWH, 3/5 (60%) for MILD PWH, 18/19 (94.74%) for SEV PWOH and 14/19 (73.68%) for MILD PWOH).
CONCLUSIONS: PWH develop a comparable short and long-term natural functional cellular and humoral immune response than PWOH convalescent patients, which are highly influenced by the clinical severity of the COVID-19 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
AIDS (London, England) - 36(2022), 10 vom: 01. Aug., Seite 1373-1382 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Donadeu, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 27.07.2022 Date Revised 28.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/QAD.0000000000003276 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342515500 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342515500 | ||
| 003 | DE-627 | ||
| 005 | 20231226014308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QAD.0000000000003276 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342515500 | ||
| 035 | |a (NLM)35730384 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Donadeu, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2022 | ||
| 500 | |a Date Revised 28.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: While the course of natural immunization specific to SARS-CoV-2 has been described among convalescent coronavirus disease 2019 (COVID-19) people without HIV (PWOH), a thorough evaluation of long-term serological and functional T- and B-cell immune memory among people with HIV (PWH) has not been reported | ||
| 520 | |a METHODS: Eleven stable PWH developing mild ( n = 5) and severe ( n = 6) COVID-19 and 39 matched PWOH individuals with mild (MILD) ( n = 20) and severe (SEV) ( n = 19) COVID-19 infection were assessed and compared at 3 and 6 months after infection for SARS-CoV-2-specific serology, polyfunctional cytokine (interferon-γ [IFN-γ], interleukin 2 [IL-2], IFN-γ/IL-2, IL-21) producing T-cell frequencies against four main immunogenic antigens and for circulating SARS-CoV-2-specific immunoglobulin G (IgG)-producing memory B-cell (mBc) | ||
| 520 | |a RESULTS: In all time points, all SARS-COV-2-specific adaptive immune responses were highly driven by the clinical severity of COVID-19 infection, irrespective of HIV disease. Notably, while a higher proportion of mild PWH showed a higher decay on serological detection between the two time points as compared to PWOH, persistently detectable IgG-producing mBc were still detectable in most patients (4/4 (100%) for SEV PWH, 4/5 (80%) for MILD PWH, 10/13 (76.92%) for SEV PWOH and 15/18 (83.33%) for MILD PWOH). Likewise, SARS-CoV-2-specific IFN-γ-producing T-cell frequencies were detected in both PWH and PWOH, although significantly more pronounced among severe COVID-19 (6/6 (100%) for SEV PWH, 3/5 (60%) for MILD PWH, 18/19 (94.74%) for SEV PWOH and 14/19 (73.68%) for MILD PWOH) | ||
| 520 | |a CONCLUSIONS: PWH develop a comparable short and long-term natural functional cellular and humoral immune response than PWOH convalescent patients, which are highly influenced by the clinical severity of the COVID-19 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Interleukin-2 |2 NLM | |
| 700 | 1 | |a Tiraboschi, Juan Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Scévola, Sofía |e verfasserin |4 aut | |
| 700 | 1 | |a Torija, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Meneghini, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Jouve, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Favà, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Calatayud, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Ardanuy, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Cidraque, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Preyer, Rosemarie |e verfasserin |4 aut | |
| 700 | 1 | |a Strecker, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Lozano, Juan J |e verfasserin |4 aut | |
| 700 | 1 | |a Podzamczer, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Bestard, Oriol |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AIDS (London, England) |d 1988 |g 36(2022), 10 vom: 01. Aug., Seite 1373-1382 |w (DE-627)NLM012619280 |x 1473-5571 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:10 |g day:01 |g month:08 |g pages:1373-1382 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAD.0000000000003276 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 10 |b 01 |c 08 |h 1373-1382 | ||